Study name | Singh B 2022a |
Title | Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: a pilot hypothesis generating study |
Overall design | The aim of this study was to gain insights into metabolic changes that relates to the ketamine response in treatment-resistant depression patients. Nine subjects with treatment-resistant depression were included. Using a comprehensive non-targeted metabolomics platform, the correlation between change in baseline peripheral metabolites after a 40 min ketamine infusion followed by recovery (change in metabolites in 24 hrs) with ketamine treatment response were investigated. Then a targeted acylcarnitine platform was used to measure 35 acylcarnitines, focusing on the early (baseline to 40 min) and late changes (100 min to 24 h post-infusion) in acylcarnitines and ketamine response in patients with treatment-resistant depression. |
Type2; Type4; | |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Treatment-resistant depression; Treatment-resistant depression; |
Criteria for depression | DSM-5 diagnosed MDD, PHQ-9 >= 15 |
Sample size | 9 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; LC-MS: Exion AD liquid chromatograph (Sciex, Framingham, MA) with QTRAP 6500+ (Sciex); |
PMID | |
DOI | |
Citation | Singh B, MahmoudianDehkordi S, Voort JLV, et al. Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: a pilot hypothesis generating study. Psychiatry Res. 2022 Aug;314:114655. |
Metabolite |